Incyte Corporation (0J9P.L)

84,13 -0,54 (-0,63%) Al 06:55PM GMT. Mercato aperto.

Incyte Corporation

1801 Augustine Cut-Off
Wilmington, DE 19803
United States
302 498 6700
https://www.incyte.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 2.094

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Herve Hoppenot	Chairman, Pres & CEO	2,36M	N/D	1960
Ms. Christiana Stamoulis MBA	Exec. VP & CFO	967,48k	N/D	1971
Ms. Maria E. Pasquale J.D.	Exec. VP, Gen. Counsel & Corp. Sec.	867,6k	16,13k	1966
Dr. Barry P. Flannelly M.B.A., MBA, Pharm.D.	Exec. VP & GM of North America	842,85k	N/D	1958
Dr. Steven H. Stein M.D.	Exec. VP & Chief Medical Officer	983,84k	119,09k	1967
Mr. Thomas Tray	VP of Fin., Chief Accounting Officer & Controller	N/D	N/D	1978
Mr. Michael James Morrissey	Exec. VP & Head of Global Technical Operations	N/D	N/D	1964
Dr. Dashyant Dhanak Ph.D.	Exec. VP & Chief Scientific Officer	N/D	N/D	1961
Ms. Christine Chiou	Head of Investor Relations	N/D	N/D	N/D
Ms. Pamela M. Murphy	VP of Investor Relations & Corp. Communications	N/D	N/D	1951

Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Governance aziendale

L'ISS Governance QualityScore di Incyte Corporation al 1 febbraio 2023 è 6. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 5; diritti degli azionisti: 5; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.